取得演示
Now livetag icon
The official Gen AI Landscape report for 2026 is here. Don’t miss out!Get your copybanner icon
Recludix Pharma

7月 2026

7月 2026Recludix Pharma的市場佔有率分析

Advancing potent and selective inhibitors 
for challenging protein targets Recludix is a clinical-stage company with leading, innovative platform approaches to discover and develop novel inhibitors for the toughest protein targets. The company’s management team includes industry veterans with a track record of success, including former leaders of Seagen, Blueprint Medicines, and Lilly. Recludix has developed […]
行業: N/A
成立年份2019
僱員51 - 200
年度營收--
recludixpharma.com
Recludix Pharma
Recludix Pharma(包含公司地區)
  • recludixpharma.com
    recludixpharma.com
查看更多網站流量與參與度資訊

Recludix Pharma的熱門網域總造訪量

了解Recludix Pharma市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

Recludix Pharma的熱門網域平均造訪時長

分析Recludix Pharma參與度指標。

過去 3 個月平均造訪時長

子公司細目
recludixpharma.comrecludixpharma.com00:00:18
透過銷售情報查看更多內容

Recludix Pharma的熱門網域平均頁面瀏覽量

了解Recludix Pharma如何保持使用者的參與度、培養其興趣,並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

想要取得更深入的流量洞見?

篩選超過 2,030 萬家線上企業。在流量激增、開始或停止使用技術或獲得正面評價時,發現新的潛在客戶。


Recludix Pharma按網域劃分的熱門競爭對手

看起來這裡的數據不足

無可顯示數據

標竿分析您的數位績效

辨識高價值機會,追蹤績效並贏得市場。


使用的熱門技術Recludix Pharma

这些是Recludix Pharma顶级域名使用的行业网站技术

小工具 (3)

內容管理系統 (2)

WordPress

WordPress

行動裝置 (2)

Meta Viewport

Meta Viewport

音訊視訊媒體 (1)

Vimeo

Vimeo

更多技術

4

檢視所有

準備好開發優質潛在客戶了嗎?

借助 SimilarWeb 銷售情報解決方案,了解網站能使用哪些技術來完善銷售宣傳手法,並縮短銷售週期。


新聞與訊號來自Recludix Pharma

透過 Similarweb 銷售訊號提醒,每當目標受眾出現新的機會或威脅時,你就會收到每日更新的已識別購買訊號。

新聞Recludix Pharma, Inc. attended event European Association of Allergy and Clinical Immunology (EAACI) and Revolutionizing Atopic Dermatitis (RAD) congresses on Jun 12th '26.Recludix Pharma to present preclinical asthma and dermatitis data for oral STAT6 Inhibitor REX-8756 at the European Association of Allergy and Clinical Immunology (EAACI) and Revolutionizing Atopic Dermatitis (RAD) congresses.
新聞Recludix Pharma, Inc. attended event Society for Investigative Dermatology (SID) Annual Meeting on May 15th '26.SAN DIEGO, CA, May 15, 2026 - Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today presented preclinical data for REX-8756 demonstrating its potent preclinical efficacy and differentiated safety profile in a model of atopic dermatitis at the Society for Investigative Dermatology (SID) Annual Meeting.
新聞Recludix Pharma, Inc. recognized as 2024 Fierce 15 biotech company.Recludix was named a 2024 Fierce 15 biotech company.

查看所有Recludix Pharma信號

讓銷售團隊專注於最有希望的機會。透過安排機會的優先順序,並在正確的時間參與,您可將工作最佳化,並完成更多交易。